We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current BPBCF market cap is 0. The company's latest EPS is JPY and P/E is N/A.
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 11.3M | 2.5M | 15.41M | 5.28M | 72k |
| Operating Income | -1.86B | -1.74B | -1.48B | -1.48B | -1.16B |
| Net Income | -1.86B | -1.72B | -1.48B | -1.49B | -1.17B |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 3.47B | 3.75B | 2.77B | 1.7B | 1.23B |
| Total Liabilities | 239.4M | 211.79M | 239.73M | 133.9M | 251.27M |
| Total Equity | 3.24B | 3.54B | 2.53B | 1.57B | 978.99M |
| Year End 31 March 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | -1.78B | -1.77B | -1.51B | -1.2B | -1.16B |
| Investing | -106.88M | -36.21M | -17.57M | -1.76M | -7.65M |
| Financing | 8.52M | 2.05B | 569.23M | 432.1M | 690.96M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 64.84M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | BrightPath Biotherapeutics Company Ltd (GM) |
| Address |
2-2-4 kojimachi chiyoda, tokyo 102-0083 |
| Website | https://www.green-peptide.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
